Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

SOUTH SAN FRANCISCO, Calif., May 01, 2024 -- Denali Therapeutics Inc. , a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier ...

Related Keywords

Massachusetts ,United States ,Sabrina Paganoni ,Laura Hansen ,Suma Babu ,Seanm Healey ,Department Of Neurology ,Nasdaq ,Denali Therapeutics Inc ,Exchange Commission ,Merit Cudkowicz ,Julieanne Dorn Professor ,Harvard Medical ,Chief Medical Officer ,Massachusetts General Hospital ,South San ,Private Securities Litigation Reform Act ,Chief Medical ,Quarterly Reports ,Media Contact ,Investor Relations ,